早期肺癌SBRT局部控制定义不一致的系统综述
该系统综述检索PubMed 2006至2023年文献,纳入113项报告早期非小细胞肺癌SBRT后局部控制率的研究,发现局部控制的命名、评估解剖部位和进展判定标准存在显著异质性,2021年后研究更倾向于仅评估原发肿瘤控制,但多数未说明评估方法且使用非客观标准。
要点
- 局部控制命名多样:局部控制、局部失败、局部复发、原发肿瘤控制分别占39%、32%、24%、4%。
- 32%研究将原发灶外复发事件纳入局部控制评估,15%未说明评估解剖部位。
- 原发肿瘤控制评估使用12种不同标准,28%仅报告影像 modality,31%用RECIST或直径增50%。
核心结论
- 肺癌SBRT后局部控制评估已从包含同叶和区域淋巴结进展转向仅评估原发肿瘤控制,但报告常缺乏客观可重复的评估方法。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索PubMed 2006至2023年文献,最终纳入113项报告早期NSCLC SBRT后局部控制或原发肿瘤控制率的研究。
主要发现
- 155项研究中113项符合纳入标准,局部控制判定术语以局部控制(39%)、局部失败(32%)、局部复发(24%)、原发肿瘤控制(4%)报告。
- 32%的研究将原发肿瘤部位以外的复发事件纳入局部控制评估,评估部位包括同叶、同侧肺、区域淋巴结分别占68%、11%、4%、2%,15%未说明解剖部位。
- 2021年后发表的研究更严格,95.7%将局部控制评估限于原发肿瘤控制。
- 原发肿瘤控制评估使用12种不同标准,28%报告特定影像 modality(CT或PET),31%采用RECIST或直径增加达50%,18%采用最短增长持续时间(2-36个月或系列变化),1%采用组织病理学确认。
关键数值与推荐
- 局部控制术语使用:局部控制39%、局部失败32%、局部复发24%、原发肿瘤控制4%。
- 解剖部位评估:同叶68%、同侧肺11%、区域淋巴结4%、其他2%,15%未说明。
- 2021年后研究95.7%仅评估原发肿瘤控制。
- 原发肿瘤控制评估标准:影像 modality 28%、RECIST或直径增50% 31%、最短增长持续时间18%、组织病理确认1%。
临床怎么用
- 未来报告SBRT后局部控制率时应明确说明评估的解剖部位、原发肿瘤控制的客观测量方法及治疗后最低随访持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Assessments of local control (LC) following stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC) play a crucial role in evaluating treatment efficacy. However, there is significant variability in how LC is defined and assessed across studies, making it challenging to compare outcomes and establish standardized benchmarks. This heterogeneity impacts clinical decision-making, prognostic assessments, and interpretations of lung SBRT efficacy in both research and clinical practice. METHODS: A systematic review was conducted following PRISMA guidelines to identify criteria used in reporting post-SBRT local control (LC) rates. A comprehensive PubMed search identified studies published between 2006 and 2023 reporting LC or primary tumor control (PTC) rates following SBRT for early-stage NSCLC. Eligible studies were independently reviewed, and LC definitions were categorized based on the anatomical sites considered and the criteria used to define treatment site progression. RESULTS: Of 155 studies identified, 113 met the inclusion criteria. LC determinations were described as 'local control', 'local failure', 'local recurrence', or 'primary tumor control' in 39%, 32%, 24%, and 4% of studies, respectively. Anatomic sites assessed for LC included recurrence events outside of the primary tumor site in 32% of studies. These LC assessments included progression within the same lobe, ipsilateral lung, and regional nodes in 68%, 11%, 4%, and 2% of studies, respectively; 15% did not specify the anatomical location(s) evaluated. Articles published after 2021 were more restrictive and limited LC evaluations to PTC in 95.7%. Regarding PTC evaluations, 12 different criteria were used ranging from reporting the specific imaging modality used (CT or PET), growth threshold assessed by Response Evaluation Criteria in Solid Tumors (RECIST) or up to 50% increase in diameter, minimum growth duration (2-36 months or serial changes), or histopathological confirmation in 28%, 31%, 18%, and 1%, respectively. CONCLUSIONS: LC evaluations following lung SBRT have evolved away from considering progression events in the same lobe and regional lymph nodes. Studies reporting PTC rates often do not state the assessment methods used and utilize non-objective criteria that may not be reproducible. Future studies reporting post-SBRT LC rates should clearly state the anatomic sites considered, document the objective measures used for PTC assessments, and report the minimum duration of post-treatment surveillance to better inform future research aiming to improve post-SBRT monitoring strategies.
引用
- Nourmohammadi N, Kashani C, Oughourlian T, et al. Inconsistent definitions of local control for stereotactic body radiation therapy for early-stage lung cancer - A systematic review. Radiother Oncol. 2026. PMID: 42431270. doi:10.1016/j.radonc.2026.111695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。